These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 3875606

  • 41. In vitro evaluation of U63196-E (AC-1370): antimicrobial activity, beta-lactamase stability, and beta-lactamase inhibition.
    Jones RN.
    Diagn Microbiol Infect Dis; 1984 Apr; 2(2):161-7. PubMed ID: 6425005
    [Abstract] [Full Text] [Related]

  • 42. The in-vitro activity and beta-lactamase stability of carumonam.
    Neu HC, Chin NX, Labthavikul P.
    J Antimicrob Chemother; 1986 Jul; 18(1):35-44. PubMed ID: 3531143
    [Abstract] [Full Text] [Related]

  • 43. In vitro and in vivo antibacterial activities of carumonam (AMA-1080), a new N-sulfonated monocyclic beta-lactam antibiotic.
    Imada A, Kondo M, Okonogi K, Yukishige K, Kuno M.
    Antimicrob Agents Chemother; 1985 May; 27(5):821-7. PubMed ID: 3874598
    [Abstract] [Full Text] [Related]

  • 44. In vitro antibacterial activity and beta-lactamase stability of the new carbapenem SM-7338.
    Sumita Y, Inoue M, Mitsuhashi S.
    Eur J Clin Microbiol Infect Dis; 1989 Oct; 8(10):908-16. PubMed ID: 2512140
    [Abstract] [Full Text] [Related]

  • 45. Susceptibility of anaerobic bacteria to Sch 34343 and other beta-lactam antibiotics.
    Jacobus NV, Tally FP, Gorbach SL.
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():189-91. PubMed ID: 4030547
    [Abstract] [Full Text] [Related]

  • 46. In vitro antibacterial activity and beta-lactamase stability of CL 118523, an aminothiazolyl iminomethoxy cephalosporin.
    Chin NX, Neu HC.
    Chemioterapia; 1987 Oct; 6(5):329-36. PubMed ID: 3322588
    [Abstract] [Full Text] [Related]

  • 47. Comparison of in vitro activity of FCE 22101, a new penem, with those of other beta-lactam antibiotics.
    Wise R, Andrews JM, Danks G.
    Antimicrob Agents Chemother; 1983 Dec; 24(6):909-14. PubMed ID: 6607032
    [Abstract] [Full Text] [Related]

  • 48. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM, Ueno Y, Cunha BA.
    Chemotherapy; 1996 Dec; 42(5):334-42. PubMed ID: 8874972
    [Abstract] [Full Text] [Related]

  • 49. Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum beta-lactamases.
    Chanal C, Sirot D, Chanal M, Cluzel M, Sirot J, Cluzel R.
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():133-41. PubMed ID: 2808205
    [Abstract] [Full Text] [Related]

  • 50. Antibacterial activity of T-5575, a novel 2-carboxypenam, and its stability to beta-lactamase.
    Matsumura N, Minami S, Mitsuhashi S.
    J Antimicrob Chemother; 1997 Jan; 39(1):31-4. PubMed ID: 9044025
    [Abstract] [Full Text] [Related]

  • 51. Sch 29482, a new oral penem: comparative in-vitro activity, beta-lactamase stability and inhibition.
    Barry AL, Jones RN, Wilson HW, Badal RE, Thornsberry C.
    J Antimicrob Chemother; 1982 Feb; 9 Suppl C():97-112. PubMed ID: 6977536
    [No Abstract] [Full Text] [Related]

  • 52. The in-vitro activity of faropenem, a novel oral penem.
    Woodcock JM, Andrews JM, Brenwald NP, Ashby JP, Wise R.
    J Antimicrob Chemother; 1997 Jan; 39(1):35-43. PubMed ID: 9044026
    [Abstract] [Full Text] [Related]

  • 53. Antimicrobial activity, beta-lactamase stability and beta-lactamase inhibition of cefotetan and other 7-alpha-methoxy beta-lactam antimicrobials.
    Jones RN, Wilson HW.
    Diagn Microbiol Infect Dis; 1983 Mar; 1(1):71-83. PubMed ID: 6323095
    [Abstract] [Full Text] [Related]

  • 54. Beta-lactamase stability and antibacterial activity of cefpirome alone and in combination with other antibiotics.
    Bakhtiar M, Selwyn S.
    Drugs Exp Clin Res; 1989 Mar; 15(10):477-82. PubMed ID: 2698794
    [Abstract] [Full Text] [Related]

  • 55. In vitro activity of SCH-34343, a new penam, and other antimicrobial agents against clinical isolates from cancer patients.
    Rolston KV, Alvarez ME, Hoy JF, Alderman HC, Ho DH, Bodey GP.
    Chemotherapy; 1986 Mar; 32(6):506-14. PubMed ID: 3100147
    [Abstract] [Full Text] [Related]

  • 56. In-vitro activity of ceftazidime against Pseudomonas aeruginosa: and its stability to pseudomonal beta-lactamases.
    Livermore DM, Williams RJ, Williams JD.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():163-7. PubMed ID: 19802980
    [Abstract] [Full Text] [Related]

  • 57. Influence of bacterial beta-lactamase production on susceptibility in agar or broth to new cephalosporins.
    Adamsson L, Dornbusch K, Hallander HO.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():153-62. PubMed ID: 19802979
    [Abstract] [Full Text] [Related]

  • 58. In vitro activity of cefotaxime against clinically significant pathogens.
    Nakashio S, Nakamura M.
    Drugs; 1988 Sep; 35 Suppl 2():14-21. PubMed ID: 3260852
    [Abstract] [Full Text] [Related]

  • 59. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
    Jones RN, Huynh HK, Biedenbach DJ, Fritsche TR, Sader HS.
    J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
    [Abstract] [Full Text] [Related]

  • 60. Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability.
    Neu HC, Labthavikul P.
    Antimicrob Agents Chemother; 1982 Jan; 21(1):180-7. PubMed ID: 6979306
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.